Health topic

Ovarian cancer

Assure her with the certainty she needs.

Most general practitioners will see a woman with undiagnosed ovarian cancer only once every few years, making it an unlikely consideration in their diagnostic thinking. In the majority of women with ovarian cancer, by the time the diagnosis is made, the cancer is at a late stage: in these women, the 5 year survival rate is less than 30 percent.1

Up until now, current testing methods such as ultrasounds or blood tests (in which we measure two proteins, CA125 and HE4) have not been shown to effectively diagnose ovarian cancer in its early stages. Therefore, screening of healthy women for ovarian cancer by these methods has not been endorsed in medical guidelines.

A new approach to better assess the risk of epithelial ovarian cancer in women with a pelvic mass uses the combination of CA 125 and HE4 in a mathematical algorithm along with the menopausal status of the woman. the dual marker combination can be used to classify women into high and low risk groups, allowing for effetive triage of women to appropriate sugical centers for care. The Risk of Ovarian Maliganacy Algorithm has been shown to increase the sensitivity and specificity for ovarian cancer detection compared to testing with CA 125 alone.

alt
Answer her ovarian cancer questions with definitive results.
 

With a broad menu of highly specific tumor marker assays and use of the Risk Of Malignancy
Algorithm (ROMA)1 Calculation Tool, you can stratify patients into low- or high-risk groups.
This accurate, meaningful guidance can help you make important treatment decisions and:

alt

 

Ovarian
The importance of the ROMA Calculation Tool
HE4 The ROMA Calculation Tool increases the diagnostic value of the dual marker combination HE4 and CA 125. The algorithm also includes a woman’s menopausal status, allowing more accurate stratifi cation of patients into low- or high-risk groups.4
CA125
ROMA Calculation Tool
Find out how Roche can help you give her the assurance she needs with accurate, meaningful results on the spot. Call (800) 346-8606 (select option 2).
Learn more

References

1. AMC-What is Ovarian Cancer-2014-Lab Women's Health Ovarian Cancer -Literature. 

2. Roche HE4 Package Insert. 

3. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Tropé C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16(1):11-17. 

4. Roche ROMA Package Insert. 

5. Moore RG, Hawkins DM, Miller MC, et al. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. Gynecol Oncol. 2014;135:547-551.

Products
Category
Found 0 results in
Filters
...
    ...